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ABSTRACT
CCN family protein 2/connective tissue growth factor (CCN2/CTGF) is a unique molecule that promotes
the entire endochondral ossification process and regeneration of damaged articular cartilage. Also, CCN2
has been shown to enhance the adhesion and migration of bone marrow stromal cells as well as the growth
and differentiation of osteoblasts; hence, its utility in bone regeneration has been suggested. Here, we
evaluated the effect of CCN2 on the regeneration of an intractable bone defect in a rat model. First, we
prepared two recombinant CCN2s of different origins, and the one showing the stronger effect on oste-
oblasts in vitro was selected for further evaluation, based on the result of an in vitro bioassay. Next, to
obtain a sustained effect, the recombinant CCN2 was incorporated into gelatin hydrogel that enabled the
gradual release of the factor. Evaluation in vivo indicated that CCN2 continued to be released at least for
up to 14 days after its incorporation. Application of the gelatin hydrogel–CCN2 complex, together with a
collagen scaffold to the bone defect prepared in a rat femur resulted in remarkable induction of osteo-
blastic mineralization markers within 2 weeks. Finally, distinct enhancement of bone regeneration was
observed 3 weeks after the application of the complex. These results confirm the utility of CCN2 in the
regeneration of intractable bone defects in vivo when the factor is incorporated into gelatin hydrogel.
INTRODUCTION
BONE LOSS IS ONE OF the most common complications inthe field of orthopedics. For example, fractures in
cancellous bone, such as in the proximal humerus, the distal
radius, or the tibial plateau, often lead to impaction of bone;
consequently, a defect results after reduction. Autologous
bone grafting is widely accepted as the gold standard for the
treatment of bone defects and nonunions. However, autol-
ogous bone grafting has some serious drawbacks, such as
prolonged operation time and donor site morbidity in about
10–30% of the cases.1 To avoid the problems associated
with autologous bone grafting, there has been a continuous
interest in the use of synthetic bone grafts during the past
few decades. The most frequently used synthetic bone grafts
are calcium phosphate ceramics, such as hydroxyapatite,
which is known for its excellent biocompatibility.2–4 How-
ever, in addition to such a physical scaffold, it has been
recognized that additional factors to stimulate intrinsic os-
teogenesis may be necessary for generating new bone with
structural and functional integrity.
Bone regenerative therapy is one of the advanced thera-
peutic methods based on tissue engineering techniques,
which has been developed recently in the field of orthopedics
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and dental medicine. In general, it is believed that efficient
regeneration of bone defects can be achieved by the com-
bination of three regenerative elements—a scaffold, cells,
and growth factor(s). As scaffolds, a number of biomaterials,
such as bioceramics, biopolymers, and synthetic polymers,
have been innovated, improved, and actually applied clini-
cally to date.5,6 Utility of mesenchymal stem cells has been
recently established as a potential component for use in bone
repair.7,8 Also, several growth factors, including fibroblast
growth factors (FGFs)9,10 and bone morphogenetic proteins
(BMPs),11,12 have been evaluated to be used in bone regen-
eration therapy. Although a few of them are already shown
to be functional and applied to bone regeneration, further
investigation to discover, or specify another ideal one is still
expected today.
CCN family protein 2/connective tissue growth factor
(CCN2/CTGF) is one such candidate to be utilized in mes-
enchymal tissue regeneration.13–17 Unlike other growth
factors, this factor belongs to a novel family of signal mod-
ulators, the CCN family,18–22 which comprises six mem-
bers in mammals. CCN is an acronym of the assemblage of
three classical members, Cyr61, CTGF, and NOV, and all
of the members are commonly characterized by their unique
primary structure. Except for trimodular CCN5, four con-
served modules are connected tandem therein. The modules
are designated: insulin-like growth factor binding protein
(IGFBP), von Willebrand factor type C repeat (VWC),
thrombospondin type 1 repeat (TSP1), and C-terminal (CT)
modules.18,19,22 All of these modules are highly interactive
with various biomolecules, and thus CCN proteins are ca-
pable of conducting the extracellular signaling network to
exert multiple functions in a variety of tissues.
Among the six members, the effect of CCN2 in mesen-
chymal tissue regeneration has been best evaluated, and its
utility is firmly indicated. Indeed, CCN2 promotes the pro-
liferation and differentiation of fibroblasts, chondrocytes,
vascular endothelial cells, and osteoblasts in vitro.23–27 It
should be also noted that CCN2 enhances the adhesion and
migration of human bone marrow mesenchymal stem cells,
which differentiate into osteoblasts to play a central role in
bone regeneration.28,29 Further, application of CCN2 to full-
thickness articular cartilage defects and osteoarthritic le-
sions in rat models remarkably promoted articular cartilage
repair in vivo.16 In that study, a gelatin hydrogel was em-
ployed to enable gradual and sustained supply of the growth
factor in vivo.16 Importantly, CCN2 gene expression was
shown to be upregulated during fracture healing in a mouse
model and during distraction osteogenesis in a rat model,30
suggesting that CTGF/CCN2 may play a critical role in
bone repair in vivo. In addition, the fact that CCN2 is
abundantly involved in platelets and is released upon their
activation indicates CCN2 to be a natural regenerator of
damaged tissues.31,32 Recent reports clearly indicate the
utility of platelet-rich plasma (PRP) in accelerating bone
and cartilage regeneration, and their findings further suggest
the utility of CCN2 in bone regenerative therapy.33 Here, we
evaluated the effect of CCN2 in relatively intractable bone
defects in a rat model in vivo, in combination with gelatin
hydrogel, which had successfully assisted CCN2 in re-
generating articular cartilage in our previous study.
MATERIALS AND METHODS
Preparation of recombinant CCN2
Two different types of recombinant CCN2 proteins
were prepared. One was an affinity-purified human CCN2
from a stable HeLa cell clone that had been transformed
by a CCN2 overexpression plasmid, as described previ-
ously.26 The other was a commercially available (Bio-
vender, Heidelberg, Germany) Escherichia coli–produced
CCN2 protein. These two proteins were functionally char-
acterized in vitro, to select the most efficient one to be used
in subsequent in vivo experiments.
Preparation of gelatin hydrogel
Gelatin with a molecular weight of 99,000 and an iso-
electrical point (pi) of 5.0 was prepared by alkalinization
followed by thermal denaturation of bovine bone (kindly
supplied by Nitta Gelatin, Osaka, Japan). Gelatin hydrogel
microspheres were prepared by cross-linking acidic gelatin
with glutaraldehyde, as described previously.10 The resul-
tant hydrogel was composed of 95% H2O and 5% gelatin
microspheres of 30–37 mm.
In vitro CCN2 retention studies
To verify the incorporation of the CCN2 into the gelatin
hydrogel, 0.5 mg of HeLa CCN2 was mixed with 1mg of
the gelatin hydrogel in 10 mL of phosphate-buffered saline
(PBS) and was incubated at 258C for 1 h. Afterward, the
hydrogel–CCN2 complex was suspended in 100 mL of PBS
and immediately recollected by centrifugation. Then, CCN2
retained in, or immediately released from the hydrogel was
analyzed by Western blotting analysis with an anti-human
CCN2 monoclonal antibody, as described previously.31 Si-
milarly, the hydrogel–CCN2 complex was further incubated
in PBS at 378C for 3, 7, or 14 days, and the hydrogel was
thereafter recollected by centrifugation. CCN2 retained in
the hydrogel was extracted by a lysis buffer,31 and was
quantified by an established ELISA system.31
In vivo CCN2 release studies
For the evaluation of the gradual release of CCN2 in vivo
(Fig. 2), 125I-labeled CCN2 (160,000 cpm) was prepared
and incorporated as described previously34 into the gelatin
hydrogel, and the gel (without a scaffold) was then im-
planted into the back subcutis of 6-week-old female ddY
mice (Shimizu Laboratory Supply, Kyoto, Japan) at the
midline 15mm from the tail root, following an established
protocol.10 At selected time points, the skin on the back of
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mice including the remaining gel was excised as a 35 cm
strip, after which the radioactivity was measured with a
gamma counter (Aloka, Tokyo, Japan) to assess the retention
profile of CCN2 in vivo, as previously described.35 The
experimental group comprised three mice unless otherwise
stated.
Preparation of CCN2–gelatin hydrogel–collagen
complex for in vivo bone regeneration
CCN2 was absorbed into the gelatin hydrogel by mixing
1mg of lyophilized gelatin hydrogel microspheres with 0
(control), 0.5, or 1 mg of CCN2 in 10 mL of a PBS, which was
then incubated at 258C for 1 h. The CCN2–gelatin hydrogel–
collagen sponge composite was prepared by lyophilizing
the mixture of CCN2 (0.5 or 1 mg), gelatin hydrogel (1mg)
and an acidic collagen solution (100 mL: I-PC containing
type I athelocollagen from Bovine dermis; Koken, Tokyo,
Japan).
Cell culture
Normal osteoblasts were obtained from the calvaria of
mice and seeded into wells of a 48-well plate at a density of
20,000 per cm2 in Dulbecco’s modified Eagle’s minimum
essential medium (D-MEM) supplemented with 10% fetal
bovine serum (FBS). After 2 days, the cells were reple-
nished with D-MEM with 0.5% FBS for 24 h and then
treated with 50 ng/mL of CCN2 or an equal volume of PBS
(control) for another 24 h in the same medium for the
comparative evaluation of the metabolic activity.
Determination of cell metabolic activity
The metabolic activity of the mouse osteoblasts was eval-
uated by the tetrazolium salt 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT; Sigma, St. Louis,
MO) assay, as previously described.36 Briefly, 50 mL of
0.5% MTT in distilled water was added to 500 mL of me-
dium in each well. After incubation for 4 h at 378C, the
cells were lysed in 500 mL of 0.04M hydrochloric acid 2-
propanol. Then, the absorbance of the lysate was measured
at a wavelength of 570 nm (excitation: 630 nm).
In vivo implantation studies
Bone regeneration was evaluated by using the estab-
lished rat model described previously.37 Briefly, 11-week-
old Wistar rats were anesthetized with an intraperitoneal
injection of Nembutal at a dose of 40mg/kg body weight.
After a parapatellar incision had been made, the articular
part of the femur was exposed, and a bone defect was
prepared in the left distal femur at the medial condyle by
drilling a channel of 2.8mm in diameter with a drill bit.
Immediately after the preparation of the bone defect, the
CCN2–gelatin hydrogel–collagen sponge composite was
applied to each defect. The femur was repositioned, and the
incision was closed with nylon sutures. After the operation,
the animals were fed ad libitum and allowed to move
around freely in their cages. One, 2, or 3 weeks after the
operation, the rats were deeply anesthetized with an intra-
peritoneal injection of ketaral (100mg/kg body weight)
and processed for sampling. Four animals were prepared,
processed, and analyzed in each group in all of the exper-
iments. The Animal Committee of Okayama University
Graduate School of Medicine, Dentistry, and Pharmaceu-
tical Sciences approved all of these experimental proce-
dures.
RNA extraction and real-time reverse transcription–
mediated polymerase chain reaction analysis
One and 2 weeks after the operation, tissues including
the operated area in the center were dissected, isolated, and
subjected to total RNA extraction. RNA extraction was per-
formed by the acid guanidium phenol-chloroform method
using a commercially available reagent (ISOGEN; Nip-
pon Gene, Tokyo, Japan). Total RNA was then reverse-
transcribed to cDNA by avian myeloblastosis virus (AMV)
reverse transcriptase with oligo d(T) as a primer, which was
supplied as a kit package (RNA PCR kit; Takara, Tokyo,
Japan), following exactly the manufacturer’s protocol.
Quantitative real-time PCR was carried out by using a
LightCycler system (v1.5; Roche, Basel, Switzerland) with
LC DNA Master SYBR Green I (Roche). Primers used for
the amplification of each cDNA were as follows: osteocal-
cin sense, 50-agctcaaccccaattgtgac-30, and antisense, 50-agct
caaccccaattgtgac-30; alkaline phosphatase sense, 50-gagcag
gaacagaagtttgc-30, and antisense, 50-gttgcagggtctggagagta-30;
glyceraldehyde 3-phosphate dehydrogenase sense, 50-catc
aagaaggtggtgaagcag-30, and antisense, 50-cgtcaaaggtggagg
agtgg-30. PCR reactions consisted of 5min of constant heat-
ing at 958C, followed by 50 cycles of amplification com-
prising 10 s of denaturation at 958C, 10 s of annealing at
608C, and 10 s of extension at 728C, followed by a melting
curve analysis to confirm the formation of the proper PCR
product, as described previously.38
Histological examination and quantification
of regenerated bone
After the operation, bone regeneration was monitored
along a time course by X-ray radiography. Animals were
processed for histological analysis at 3 weeks after the op-
eration, when bone regeneration became evident in the
CCN2-treated groups by X-ray examination. At the day of
sampling, the rats were anesthetized and perfused with 4%
paraformaldehyde, and the femur was then dissected and
further fixed overnight at 48C in the same solution. After
having been decalcified with 10% ethylene-diamine tetra-
acetate (EDTA) for 2 weeks, the samples were embedded
in paraffin according to an established procedure.30 Paraffin
sections were prepared from these samples, deparaffinized
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with xylene, rehydrated stepwise, and washed with PBS.
The sections (6 mm in thickness) were stained with hema-
toxylin and eosin by a standard protocol, and examined
under a light microscope.
Quantification of the regenerated bone was performed by
examining the images of the stained sections. Total area of
regenerated bone in the region of the defect prepared was
computed by using version 1.62 of NIH image public do-
main software. With the data obtained, the bone regener-
ation index was calculated as the percentage of the area
occupied by the regenerated bone against the whole area
evaluated.
Statistical analysis
The results obtained from quantitative experiments were
reported as the mean values standard deviation (SD).
Statistical comparisons between the groups were performed
by using the nonparametric one-way analysis of variance
(ANOVA) and Tukey test at 5% significance ( p< 0.05)
with StatView software for Windows, version 5.0 (SAS
Institute, Cary, NC).
RESULTS
Comparative analysis of the effect of human
recombinant CCN2s produced by mammalian
cells and E. coli on the metabolic activity
of osteoblasts in vitro
It was previously reported that CCN2 promotes both
proliferation and differentiation of osteoblastic cells in vitro.
Therefore, to obtain best results by using the better mate-
rial in vivo, we initially evaluated the effects of the two
recombinant CCN2s (rCCN2s) currently available on the
metabolic activity of mouse primary osteoblasts in vitro. One
was a commercially obtained recombinant human CCN2
produced by E. coli, and the other was human CCN2 pro-
duced by a HeLa cell clone that had been transduced with a
mammalian expression vector of human CCN2 and purified
through two steps of affinity chromatography, as previously
described.16 Osteoblasts were cultured with either protein,
and their metabolic activity was monitored by conducting
the MTT assay. Consequently, both CCN2s were capable of
promoting the survival and metabolism of osteoblasts (Fig.
1); however, the HeLa-derived one was more potent.
Therefore, we selected the HeLa-derived rCCN2 for the
subsequent evaluation with gelatin hydrogel in vivo.
Gradual and sustained release of CCN2
by gelatin hydrogel in vivo
The gelatin hydrogel has been shown to be effective in
realizing a prolonged supply of certain growth factors when
implanted in tissues in vivo. In our previous work, we
showed that CCN2 can be efficiently incorporated into the
hydrogel by absorption without allowing immediate diffu-
sion out of the hydrogel.16 First of all, we experimentally
confirmed the efficient incorporation and gradual release of
the CCN2 in combination with the gelatin hydrogel in vitro.
As previously described, CCN2 was successfully incorpo-
rated into the gelatin hydrogel and was retained in the
hydrogel even after 14 days of incubation in PBS at 378C
(Fig. 2A). To confirm that CCN2 absorbed to the gelatin
hydrogel was also released gradually during degradation of
the hydrogel in vivo, we prepared radiolabeled HeLa-
derived recombinant CCN2 and absorbed it to the gelatin
hydrogel, after which the complex was implanted subcu-
taneously into the dorsal skin of mice, according to an
established prodedure.10 Quantitative evaluation of the ra-
dioactive CCN2 remaining at the implant site up to 2 weeks
after the impregnation indicated that at least more than 30%
of the CCN2 was still present in the hydrogel at 3 days after
the implantation (Fig. 2). Further, even after 2 weeks, im-
planted CCN2 was still detectable in the local area around
the implanted gel suggesting that CCN2 was continuously
supplied from the gelatin hydrogel complex as long as 14
days by a single local administration. Therefore, although
the speed of CCN2 release was observed to be slightly
faster than the disintegration speed of the hydrogel in vivo,10
the combination of CCN2 and gelatin hydrogel was proven
to be effective in enabling a sustained supply of this factor
FIG. 1. Effect of the two rCCN2 proteins on the proliferation of
mouse osteoblasts in primary culture. The cells were treated with
50 ng/mL of a HeLa-derived human rCCN2 (rCCN2-H) or an E.
coli–derived human rCCN2 (rCCN2-E) for 5 h, and their survival
and metabolism were then evaluated by conducting the MTT as-
say. Results are presented as the mean values of four sets of
evaluations with standard deviations (SDs). Statistically signifi-
cant differences (*p< 0.05 and **p< 0.01) between two experi-
mental groups are indicated by the brackets.
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around the local region of implantation for tissue regener-
ation in vivo.
Effects of the CCN2-absorbed gelatin hydrogel
on osteoblastic differentiation of the cells
in the regenerating bone defect in vivo
To evaluate the effect of the rCCN2–gelatin hydrogel
complex on bone regeneration, we prepared an intractable
bone defect model by following the methodology described
in a previous study.37 In that study, the effect of TGF-b on
bone regeneration was examined, but no significant effect
was found. According to the same methodology, we pre-
pared bone defects in rat femur, as illustrated in Figure 3A,
and implanted the gelatin hydrogel containing PBS only
(control) or 0.5 mg of the rCCN2, which was built in a col-
lagen sponge scaffold. After 1 and 2 weeks, the tissue in the
original defect was sampled for RNA analysis. Quantitative
real-time RT-PCR evaluation revealed that gene expression
of an osteoblastic differentiation marker gene, osteocalcin
(ocn), was remarkably elevated by the application of the
rCCN2–gelatin hydrogel complex (Fig. 3B). Another such
gene, the mineralization-associated alkaline phosphatase
gene (alp), appeared to be induced by rCCN2 as well, al-
though the increase in its expression was not statistically
significant (Fig. 3C). Therefore, the rCCN2–gelatin hydro-
gel complex was effective in promoting osteogenesis by
acting on either osteoblasts or bone marrow mesenchymal
stem cells or both, as both are targets of CCN2, through the
gradual release of rCCN2 as suggested by the data shown in
Figure 2.
Enhanced regeneration of the bone defect by
the CCN2-absorbed gelatin hydrogel in vivo
Utilizing the same bone defect model as employed
above, next we evaluated the effect of the CCN2-absorbed
gelatin hydrogel on bone regeneration. After preparation of
the bone defect, gelatin hydrogel that had been incubated
with PBS only (control), 0.5 mg of rCCN2, or 1 mg of rCCN2
and built in a collagen sponge was impregnated therein, and
the time course of bone regeneration was initially moni-
tored by X-ray radiomicrography. Since regenerated bone
was clearly observed at 3 weeks after the operation, ani-
mals were processed and the sections of the corresponding
areas were analyzed at this time point. Histological exam-
ination of the sections clearly showed that both 0.5 and 1 mg
of rCCN2 incorporated into the gelatin hydrogel clearly
promoted bone regeneration, which resulted in almost com-
plete repair of the cortical bone removed by the operation
(Fig. 4). Of note, woven bone formation indicating active
bone regeneration was clearly observed only with rCCN2
along the cortical bone–bone marrow boundary (Fig. 4E).
In contrast, control group showed only partial repair of the
bone defect with sparse bone trabeculae at the same time
point (Fig. 4A). In these cases, fibrous structure that is
supposed to be the remnant of the collagen scaffold can
be observed at the area without efficient bone formation
(Fig. 4B). Further, quantitative analysis of the histological
sections revealed significant acceleration of bone regener-
ation by rCCN2 (Fig. 5). The effects obtained with 0.5 and
1 mg of rCCN2 were comparable without statistical signif-
icance, suggesting that 0.5 mg was an optimal dose to yield
a maximal effect in promoting the regeneration of bone in
a defect of this size and location. According to previous
FIG. 2. (A) Retention of the rCCN2 in the gelatin hydrogel
in vitro. Efficient incorporation of the HeLa-derived rCCN2 in the
gelatin hydrogel was confirmed by Western blotting of the pellet
(P) and supernatant (S) fractions of the gelatin hydrogel in PBS
immediately after suspension (left panel). The gelatin hydrogel–
rCCN2 complex was further incubated in PBS at 378C for the
indicated time periods, and the CCN2 retained in the hydrogel was
quantified by ELISA. Amount of the CCN2 retained is represented
as a percentage versus the original incorporated amount at time 0.
Data represent the results of three independent experiments. Mean
values are shown with error bars of SDs. (B) Retention of the
rCCN2 in the gelatin hydrogel in the back subcutis of mice. After
the implantation of the radiolabeled rCCN2 adsorbed onto the
gelatin hydrogel, the tissue surrounding the implanted gel was
collected, and the time course of loss of radioactivity was deter-
mined. Radioactivities in the collected samples were counted, and
the relative amounts of remaining rCCN2 were computed as
percentages of the collected radioactivity versus the initial total
radioactivity in the implant. Data represent the results of the ex-
periments with three animals for each group. Mean values are
shown with error bars indicating SDs.
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reports, the dose dependence of CCN2 in both chondrocytic
and osteoblastic cells in vitro was found to be comparable
(Table 1: 50 ng/mL was sufficient to yield maximal effects).
However, an in vivo study has shown that higher dose is
required for cartilage regeneration than the bone regener-
ation performed in this study (Table 1). This in vitro–in vivo
discrepancy in CCN2 dose dependence also emphasizes the
utility of this drug delivery system, particularly in the re-
generation of this type of bone defects. Together with the
cell biological effects illustrated in Figure 3, these results
strongly indicate the efficacy of rCCN2, in combination
with gelatin hydrogel, in promoting the regeneration of
bone in intractable bone defects.
DISCUSSION
We initiated this study by reevaluating the biological
activity of our original rCCN2 derived from a HeLa
transformant in comparison with that of a commercially
available one to obtain the best results in vivo. After con-
firming the better effect of our rCCN2 on osteoblast sur-
vival and metabolism, we next examined if the combination
of the gelatin hydrogel and rCCN2 was suitable for the
sustained administration of rCCN2 by local application
in vivo. Since gradual release of rCCN2 was confirmed, we
finally applied the CCN2–gelatin hydrogel complex to an
intractable bone defect model prepared in a rat femur. As a
result of the application of 0.5–1 mg of rCCN2 incorporated
into the gelatin hydrogel with a collagen sponge scaffold,
regeneration of the bone defect was markedly accelerated,
which was preceded by the induction of several genes that
were critical for osteoblast differentiation, mineralization,
and bone remodeling. These results strongly indicate the
utility of gelatin hydrogel–absorbed CCN2 as a therapeutic
for the treatment of intractable bone defects.
The difference in the biological activity observed in vitro
between the two recombinant proteins would supposedly
be due to the organism that produced these proteins. In
mammalian cells, proteins can be posttranslationally mod-
ified in the endoplasmic reticulum and Golgi apparatus; this
modification obviously results in molecules structurally
different from those produced by prokaryotes. Indeed, in
the case of mammalian cell–derived CCN2, N-linked gly-
cosylation occurs at two asparagine residues, whereas this
cannot occur in the E. coli–derived one.39 Together with
other possible side chain modifications, such glycosylation
may well result in a tertiary structure different from that of
E. coli–derived CCN2. However, in this study, we evalu-
ated the CCN2 activity only in terms of osteoblast survival
and metabolism. It should be noted that CCN2 is a multi-
functional protein with multiple targets. Therefore, even if
E. coli–derived CCN2 is not active enough in this particular
situation, it can be as active as a mammalian cell–derived
CCN2 in other functional aspects. Further analysis with
FIG. 3. (A) Schematic representation of the bone defect prepared
in the rat model. The cortical bone (2.8mm in diameter) of the
operated area was completely removed by drilling as illustrated,
and the gelatin hydrogel complex was implanted therein. (B, C)
Effect of the gelatin hydrogel–absorbed CCN2 built in a collagen
sponge on the expression of osteocalcin and alkaline phosphatase
genes. One or 2 weeks after the application of the hydrogel com-
plex, RNA was extracted from the regenerating tissues, including
the operated areas, and subjected to quantitative real-time PCR
evaluation. Four animals were analyzed per group. Data are pre-
sented as relative mRNA levels against those of the gapdh gene
and are plotted independently, with the average and SD values
indicated for each group. A statistically significant difference
(*p< 0.05) between the groups is indicated by the bracket.
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different bioassay systems will provide an answer for this
question, which is in progress.
As revealed in Figure 4, the cortical bone that re-
generated with the assistance of CCN2 appeared to be quite
natural, without a sign of overgrowth or atypical histolog-
ical findings that are not usually observed in normal tissues.
The regenerated cortical bone was connected seamlessly to
the original bone cortex, as the border between the two can
be noticed only by careful observation. Of note, it was
previously shown that an intractable defect in articular
cartilage could be also repaired in such an ideal manner by
the same CCN2–gelatin hydrogel complex.16 In either case,
it is critically important for the regenerative therapy to
strictly induce cartilage/bone formation up to the neces-
sary and sufficient level, avoiding any overcorrection that
may cause dysfunction. Nevertheless, other bone-inducing
growth factors are sometimes difficult to control to obtain
a desired outcome, which is partly because of their direct
and strong stimulatory effect toward bone regeneration. In
contrast, CCN2 realized the bone repair exactly at the de-
sired level without strict control of the dose. This novel
action of CCN2 is probably based on the functional prop-
erty of CCN2 as a conductor/modulator of the local extra-
cellular signaling network. Instead of executing a specific
FIG. 4. Typical histological findings observed in the bone defect area treated with (þCCN2) or not (Control) in combination with
gelatin hydrogel and collagen scaffold 3 weeks after the operation. Microscopic views of hematoxylin–eosin staining of sections
representing the groups without (A, B) and with (C–E) CCN2 are displayed. Approximate position of the edges of the operated area is
indicated by arrows. A higher magnification of the area specified in (A) and (C) in a rectangle is shown as (B) and (D), respectively.
Atypical structure supposed to be the remnant of collagen scaffold is visible in the control group (A, B). Woven bone formation (wb)
was clearly observed at the bone (b)–mesenchymal stromal tissue (me) boundary in the CCN2-treated groups (E). Scale bars: 400 mm.
Regeneration of cortical bone is clearly observed only in the group treated with the CCN2–gelatin hydrogel–collagen sponge composite
(C–E). Color images available online at www.liebertpub.com/ten.
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mission through a specific receptor, CCN2 controls the
overall status of extracellular signalings by interacting with
a number of growth factors and extracellular matrix (ECM)
components involved in osteogenesis, such as TGF-b,
BMP-4, proteoglycans, and integrins.17,19,22 Thus, the bi-
ological effects yielded by CCN2 is a net output from those
growth factors and other molecules manipulated by the four
modules of CCN2, rather than a direct and distinct effect
of CCN2 per se. As a consequence, bone regeneration is
promoted in a harmonized manner by CCN2 without atyp-
ical tissue formation or overgrowth. The property of CCN2
as a natural tissue-remodeling molecule is also indicated by
the fact that this factor is abundantly released from platelets
upon activation.31,32
From a cell biological point of view, the effect of CCN2
to promote harmonized regeneration of bone tissue can be
also interpreted as an outcome of simultaneous enhance-
ment of the growth and differentiation of most of the cell
types involved. The major producer of bone matrix is the
osteoblast; however, osteoblasts originate in mesenchymal
stem cells in bone marrow. Needless to say, proper struc-
ture and remodeling potential of regenerated bone require
the invasion by a newly formed microvasculature. In the
case of bone fracture or large bone defects, chondrocytes
temporarily appear, and the endochondral ossification pro-
cess recurs to repair the defect.30 According to previous
reports, all of the cells mentioned above are targets of
CCN2. Indeed, CCN2 promotes adhesion and migration of
human bone marrow stem cells; the proliferation, differen-
tiation, and mineralization of osteoblasts and growth plate
chondrocytes; and the migration and proliferation of vas-
cular endothelial cells in vitro.25–29 On the other hand, we
recently found that CCN2 promoted the formation of os-
teoclasts that are engaged in bone resorption (unpublished
data). In fact, pathogenic role of CCN2 in osteolytic me-
tastasis of breast cancer cells has been indicated.40 How-
ever, bone resorption is rather an essential step in the
remodeling of bone tissue during regeneration. In this way,
since all of the key cellular players in bone formation/
remodeling are together encouraged by CCN2 to regenerate
bone defects, the regeneration process follows the physio-
logical way of osteogenesis, which we consider is the cell
biological background of the observed effects of CCN2.
The gelatin hydrogel–absorbed CCN2 could successfully
promote the regeneration of bone in a relatively intractable
TABLE 1. DOSE DEPENDENCE OF THE CCN2 EFFECTS ON CARTILAGE AND BONE REGENERATION IN VITRO and IN VIVO
Target cell/tissue
CCN2 dose in vitro (ng/mL) CCN2 dose in vivo (mg/lesion)
25 50 100 0.5 1 1.5
Osteoblastic cell/bone þ þþ þþ þþ þþ ND
Chondrocytic cell/articular cartilage þ þþ þþ  þ þþ
The data with osteoblastic cells and chondrocytic cells in vitro are from Nishida et al.27 and Nakanishi et al.,25 respectively. The in vivo data of bone
regeneration are described in the present work, whereas those of cartilage regeneration are from Nishida et al.16 ND: not determined.
FIG. 5. Quantitative analysis of the regenerated bone in the
bone defect area at 3 weeks after the operation. (A) Schematic
representation of the histological area subjected to quantitative
analysis. A maximum rectangle area within the original defect was
selected, and both cortical and trabecular bone regions (shown in
pink) were integrated to represent the total quantity of regenerated
bone. (B) Results of the quantitative analysis. Four animals of
each group were treated with a gelatin hydrogel/collagen sponge
with or without CCN2, and were analyzed. Asterisks denote sig-
nificant differences (*p< 0.05) between the two groups, as indi-
cated by the brackets. Color images available online at www
.liebertpub.com/ten.
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defect of normal bone tissue to the exactly desired level.
However, it may not be effective enough to regenerate
more intractable cases with basal low regenerative potential
of the tissue, which can occur under systemic and local
pathological conditions. To obtain satisfactory results with
such difficult cases, additional material may need to be
combined with the present gelatin hydrogel–CCN2 com-
plex. In our hands, the combination of CCN2 and a porous
hydroxyapatite scaffold was earlier indicated to be effective
for the repair of larger bone defects in vivo.29 Also, it
should be noted that CCN2 is a conductor/modulator of
extracellular signaling networks to harmonize the effects of
various factors involved in the microenvironment. If so,
any other growth factor may be combined with CCN2 upon
its application for tissue regeneration to control the mode of
the action of the growth factor at a physiologically ade-
quate level. Therefore, the utility of CCN2 as a second
factor to be used in combination with a certain growth
factor is strongly suggested, which would be expected to
regenerate bone defects with pathological complexities, for
example, as those in diabetes mellitus and postmenopausal
osteoporosis.
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